Today: 9 June 2026
Browse Category

NASDAQ:RANI 17 October 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics shares jumped 248% to close at $1.64 on October 17, 2025, after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in a private placement, boosting its cash position. Rani will get $10 million upfront from Chugai and up to $175 million in milestones for its first oral drug program.
20 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···

Stock Market Today

  • Notable Options Activity Tuesday: COHR, QCOM, RH Stocks
    June 9, 2026, 4:02 PM EDT. Options trading surged in Coherent Corp (COHR), Qualcomm (QCOM), and RH on Tuesday amid heightened contract volume. COHR saw 32,203 contracts trade, representing about 3.2 million shares or 53.2% of its average daily volume, led by the $470 call expiring June 2026. QCOM's options volume hit 131,671 contracts, approximately 13.2 million shares or 52.7% of daily average, driven by the $155 put expiring July 2026. RH recorded 4,502 contracts, about 450,200 shares or 52% of daily volume, with the $165 call expiring June 2026 notably active. These volumes suggest increased investor interest in these strikes and expirations, reflecting strategic positioning in the Russell 3000 constituents.

Latest articles

POET Technologies Shares Drop; AI Photonics Trade Faces Pressure

POET Technologies Shares Drop; AI Photonics Trade Faces Pressure

9 June 2026
POET Technologies plunged 13% to $10.65 as renewed class-action reminders and April’s Marvell/Celestial AI order cancellation kept legal and execution risks in focus, outweighing a $50 million Lumilens order and $400 million financing, while broader AI chip stocks also slumped.
Uranium Energy Drops 17% After Reporting Q3 Loss

Uranium Energy Drops 17% After Reporting Q3 Loss

9 June 2026
Uranium Energy shares plunged 17% to $10.43 after reporting a wider Q3 net loss of $52.3 million and no uranium inventory sales, overshadowing the start of production at Burke Hollow; heavy volume and a sharper drop than peers reflected investor concerns over execution risks and near-term earnings despite strong cash and no debt.
Elong Power Stock Rips 58%, Small Nasdaq Battery Play Goes Wild

Elong Power Stock Rips 58%, Small Nasdaq Battery Play Goes Wild

9 June 2026
Elong Power shares soared 58.3% to $1.22 in heavy Nasdaq trading, with volume topping 123 million, after a recent $6 million unit offering at $1.30 and a March 1-for-80 reverse split; despite the rally, the stock remained below the recent offering price, with filings showing a $5.57 million net loss for 2025, a $14 million working-capital deficit, and warnings of possible further dilution if more capital is needed.
Go toTop